"Watchful Waiting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clinical management approach wherein immediate therapy is not provided but there is a period of observation during which periodic tests monitor patient and the progression of the illness. (Driffield T, Smith PC Med Decis Making. 2007 Mar-Apr;27(2):178-88)
| Descriptor ID |
D057832
|
| MeSH Number(s) |
N04.761.559.590.900
|
| Concept/Terms |
Watchful Waiting- Watchful Waiting
- Waiting, Watchful
- Waitings, Watchful
- Watchful Waitings
|
Below are MeSH descriptors whose meaning is more general than "Watchful Waiting".
Below are MeSH descriptors whose meaning is more specific than "Watchful Waiting".
This graph shows the total number of publications written about "Watchful Waiting" by people in this website by year, and whether "Watchful Waiting" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 4 | 6 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 5 | 2 | 7 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 3 | 4 |
| 2025 | 3 | 1 | 4 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Watchful Waiting" by people in Profiles.
-
Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11; 336(6):464-472.
-
Aquablation for LUTS due to BPH in men with localized prostate cancer. Can J Urol. 2026 Jun 26; 33(3):555-562.
-
Utilizing Patient Input in Rectal Cancer Trial Design. J Natl Cancer Inst. 2025 Jul 01; 117(7):1421-1428.
-
Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal. BJU Int. 2025 Sep; 136(3):447-451.
-
Projected outcomes of reduced-biopsy management of Grade Group 1 prostate cancer: implications for relabeling. J Natl Cancer Inst. 2025 Apr 01; 117(4):685-691.
-
Multi-level Factors to Build Confidence and Support in Active Surveillance for Low-Risk Prostate Cancer: A Qualitative Study. J Gen Intern Med. 2025 04; 40(5):1107-1115.
-
Management of monochorionic diamniotic twin gestation affected by Type-II selective fetal growth restriction: cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2025 01; 65(1):39-46.
-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 02; 392(1):45-55.
-
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.
-
Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer. Ann Fam Med. 2024 Jan-Feb; 22(1):5-11.